Literature DB >> 8702220

Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors.

A R Gagliardi1, B Hennig, D C Collins.   

Abstract

We have previously reported that the partial estrogen antagonists, tamoxifen, clomiphene and nafoxidine, inhibited angiogenesis in vivo in a dose-related manner in the six-day old chick egg chorioallantoic membrane (CAM) assay. In the present study, we investigated the effect of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) on the growth of porcine pulmonary artery and human dermal microvascular endothelial cells. Both of these growth factors significantly increased the growth of these cells. The antiproliferative activity of the partial antiestrogens, tamoxifen, nafoxidine and clomiphene, and the pure antiestrogen, ICI 182,780, was determined. Tamoxifen, clomiphene, nafoxidine and ICI 182,780 significantly inhibited endothelial cell growth stimulated by bFGF and VEGF. This inhibition of endothelial cells was not altered by the presence of up to 30 microM of estradiol-17 beta. These results indicate that the antiangiogenic action of the antiestrogens does not occur via the estrogen receptor, but by a direct inhibition of growth factor stimulated endothelial cell growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702220

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Changes in vascularization of human breast cancer xenografts responding to antiestrogen therapy.

Authors:  C A Kristensen; L M Hamberg; G J Hunter; S Roberge; D Kierstead; G L Wolf; R K Jain
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

2.  Inhibition of volume-regulated anion channels in cultured endothelial cells by the anti-oestrogens clomiphene and nafoxidine.

Authors:  C Maertens; G Droogmans; P Chakraborty; B Nilius
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins.

Authors:  Xuemei Chen; Ruud P M Dings; Irina Nesmelova; Stefan Debbert; Judith R Haseman; Jacques Maxwell; Thomas R Hoye; Kevin H Mayo
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

4.  Biphasic estrogen response on bovine adrenal medulla capillary endothelial cell adhesion, proliferation and tube formation.

Authors:  S K Banerjee; D R Campbell; A P Weston; D K Banerjee
Journal:  Mol Cell Biochem       Date:  1997-12       Impact factor: 3.396

Review 5.  Toward checkmate: biology and breast cancer therapy for the new millennium.

Authors:  K D Miller; G W Sledge
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

6.  Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients.

Authors:  U Coskun; N Gunel; B Sancak; E Onuk; M Bayram; A Cihan
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

7.  Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Authors:  Maura N Dickler; William T Barry; Constance T Cirrincione; Matthew J Ellis; Mary Ellen Moynahan; Federico Innocenti; Arti Hurria; Hope S Rugo; Diana E Lake; Olwen Hahn; Bryan P Schneider; Debasish Tripathy; Lisa A Carey; Eric P Winer; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

8.  Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor.

Authors:  S W McLeskey; C A Tobias; P R Vezza; A C Filie; F G Kern; J Hanfelt
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

9.  Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.

Authors:  Tiffany A Traina; Hope S Rugo; James F Caravelli; Sujata Patil; Benjamin Yeh; Michele E Melisko; John W Park; Stephanie Geneus; Matthew Paulson; Jill Grothusen; Andrew D Seidman; Monica Fornier; Diana Lake; Chau Dang; Mark Robson; Maria Theodoulou; Carlos D Flombaum; Larry Norton; Clifford A Hudis; Maura N Dickler
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

10.  Tamoxifen induction of angiogenic factor expression in endometrium.

Authors:  S Hague; S Manek; M K Oehler; I Z MacKenzie; R Bicknell; M C P Rees
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.